Showing results (21-30 of 36) with videos related to
Sort By:
Pageof 4
Hematological Oncology|September 23, 2023
Venetoclax in biomarker-selected multiple myeloma patients: Impact of exposure on clinical efficacy and safetyMohamed Badawi, Sheryl Coppola, Doerthe Eckert, et al.Journal of Cancer|May 22, 2023
Venetoclax Penetrates the Blood Brain Barrier: A Pharmacokinetic Analysis in Pediatric Leukemia PatientsMohamed Badawi, Rajeev Menon, Andrew E Place, et al.Clinical Pharmacology and Therapeutics|August 5, 2024
Coproporphyrin-I as a Selective OATP1B Biomarker Can Be Used to Delineate the Mechanisms of Complex Drug-Drug Interactions: Cedirogant Case StudyRyota Kikuchi, Yuli Qian, Mohamed Badawi, et al.Clinical Drug Investigation|July 13, 2022
Bioavailability Evaluation of Venetoclax Lower-Strength Tablets and Oral Powder Formulations to Establish Interchangeability with the 100 mg TabletMohamed Badawi, Xin Chen, Patrick Marroum, et al.Oncotarget|June 15, 2018
CD44 positive and sorafenib insensitive hepatocellular carcinomas respond to the ATP-competitive mTOR inhibitor INK128Mohamed Badawi, Jihye Kim, Anees Dauki, et al.Journal of Extracellular Vesicles|July 19, 2017
Comprehensive toxicity and immunogenicity studies reveal minimal effects in mice following sustained dosing of extracellular vesicles derived from HEK293T cellsXiaohua Zhu, Mohamed Badawi, Steven Pomeroy, et al.International Journal of Clinical Oncology|December 29, 2023
Phase 2 study of ibrutinib plus venetoclax in Japanese patients with relapsed/refractory mantle cell lymphomaHideki Goto, Satoshi Ito, Masahiro Kizaki, et al.Cell Death & Disease|February 22, 2020
Loss of RE-1 silencing transcription factor accelerates exocrine damage from pancreatic injuryJulie K Bray, Ola A Elgamal, Jinmai Jiang, et al.Journal of Extracellular Vesicles|July 19, 2017
Low active loading of cargo into engineered extracellular vesicles results in inefficient miRNA mimic deliveryDhruvitkumar S Sutaria, Jinmai Jiang, Ola A Elgamal, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 22, 2020
Early Intervention with Lenalidomide in Patients with High-risk Chronic Lymphocytic LeukemiaShanmugapriya Thangavadivel, Qiuhong Zhao, Narendranath Epperla, et al.Pageof 4